Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang concluded the patient recruitment for the clinical trial of covid-19 treatme...

[June 11, 2021]

Bukwang Pharmaceutical Co., Ltd. announced that they concluded patient recruitment for the phase 2 clinical trial of covid-19 treatment with Levovir. The number of patients is 104(the initial goal was 80 patients) and Bukwang is going to file the data right after the final patient’s clinical progression and submit it to the Ministry of Food and Drug Safety for the next steps. Clevudine, the active ingredient of Levovir®, is an antiviral drug fully developed by Bukwang. It has been under development for treating COVID-19(CLV-203) in the mild to moderate stage to find...

R&D

Bukwang concluded the patient recruitment for the clinical trial of covid-19 treatment

[June 11, 2021]

Bukwang Pharmaceutical Co., Ltd. announced that they concluded patient recruitment for the phase 2 clinical trial of covid-19 treatment with Levovir....

PRODUCTS
main_cg.jpg
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |